Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 13,055 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 13,055 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $4.20, for a total value of $54,831.00. Following the completion of the transaction, the insider directly owned 46,945 shares of the company’s stock, valued at approximately $197,169. The trade was a 21.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Khurram Jamil also recently made the following trade(s):

• On Tuesday, January 6th, Khurram Jamil sold 21,446 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.65, for a total value of $78,277.90.
• On Monday, January 5th, Khurram Jamil sold 25,499 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.90, for a total value of $99,446.10.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The shares were sold at an average price of $7.04, for a total transaction of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Stock Down 11.1%

Shares of Galectin Therapeutics stock opened at $3.45 on Wednesday. The company has a market cap of $222.42 million, a P/E ratio of -5.85 and a beta of 1.03. The firm’s 50 day moving average price is $5.30 and its 200-day moving average price is $4.39. Galectin Therapeutics Inc. has a 52-week low of $1.07 and a 52-week high of $7.13.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities research analysts forecast that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Institutional Trading of Galectin Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GALT. JPMorgan Chase & Co. increased its holdings in shares of Galectin Therapeutics by 25.4% in the third quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company’s stock valued at $66,000 after purchasing an additional 3,133 shares during the period. Hudson Bay Capital Management LP acquired a new stake in shares of Galectin Therapeutics during the third quarter worth about $63,000. Vivaldi Capital Management LP boosted its position in Galectin Therapeutics by 48.3% in the third quarter. Vivaldi Capital Management LP now owns 255,752 shares of the company’s stock valued at $1,083,000 after buying an additional 83,309 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in Galectin Therapeutics by 290.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 60,867 shares of the company’s stock worth $258,000 after buying an additional 45,297 shares during the period. Finally, Lido Advisors LLC purchased a new position in Galectin Therapeutics during the 3rd quarter worth approximately $154,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

More Galectin Therapeutics News

Here are the key news stories impacting Galectin Therapeutics this week:

• Neutral Sentiment: Regulatory disclosure: multiple Form 4 filings were submitted this week reporting the insider sales; investors can review the filings for exact timestamps and amounts. Form 4 – Jamil
• Negative Sentiment: CEO Joel Lewis sold a total of 84,000 shares across Jan. 2, 5 and 6 (average prices ~$4.20, $3.91, $3.58), raising roughly $320k and trimming his stake by a few percent. Large CEO sales can be perceived negatively by the market. Form 4 – Joel Lewis
• Negative Sentiment: CFO Jack W. Callicutt sold 60,000 shares over the same period (average prices ~$4.20–$3.67), generating roughly $233k; one filing shows his reported ownership dropping by ~72.8% after a transaction. Large, repeated sales from the CFO amplify concern about insider sentiment or liquidity needs. Form 4 – Jack Callicutt
• Negative Sentiment: Insider Khurram Jamil sold 60,000 shares across Jan. 2–6 at prices between ~$4.20 and $3.65 (~$232k total). Multiple insiders selling similar-sized blocks in the same window increases perceived downside risk. Form 4 – Khurram Jamil
• Negative Sentiment: Pomerantz LLP issued an investor alert announcing an investigation into Galectin, which may lead to litigation or heightened scrutiny and typically weighs on share price until resolved. INVESTOR ALERT: Pomerantz Investigates GALT

Analyst Ratings Changes

Several research analysts recently weighed in on the company. HC Wainwright upped their target price on Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Galectin Therapeutics has a consensus rating of “Hold” and a consensus target price of $11.00.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.